Immunohistochemical analysis of thymidylate synthase, p16INK4a, cyclin-dependent kinase 4 and cyclin D1 in colorectal cancers receiving preoperative chemotherapy: Significance of p16INK4a-mediated cellular arrest as an indicator of chemosensitivity to 5-fluorouracil

Pathology International

Volumn 54, Issue 8, 2004, Pages 564-575

  Kamoshida, Shingo ^a   Matsuoka, Hiroshi ^a   Shiogama, Kazuya ^a   Matsuyama, Atsuji ^a   Shimomura, Ryoichi ^a   Inada, Ken Ichi ^a   Maruta, Morito ^a   Tsutsumi, Yutaka ^a  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

5 fluorouracil; Colorectal cancer; Cyclin D1; p16INK4a; Thymidylate synthase

Indexed keywords

ANTIGEN; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; FLUOROURACIL; PARAFFIN; PEROXIDASE; PROTEIN P16; THYMIDYLATE SYNTHASE;

ADULT; AGED; ARTICLE; BIOPSY; CANCER CHEMOTHERAPY; CANCER SURGERY; CHEMOSENSITIVITY; COLORECTAL CANCER; CONTROL GROUP; CONTROLLED STUDY; FEMALE; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPEROXIDASE STAINING; MALE; PHENOTYPE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE;

ADENOCARCINOMA; ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; COLORECTAL NEOPLASMS; CYCLIN D1; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASES; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; PREOPERATIVE CARE; PROTO-ONCOGENE PROTEINS; THYMIDYLATE SYNTHASE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 4344710221     PISSN: 13205463     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1827.2004.01665.x     Document Type: Article

References (46)

1. Bleiberg H. Colorectal cancer: The challenge. Eur J Cancer 1996; 32A: S2-6.
2. Pinedo HM, Peters GFJ. Fluorouracil: Biochemistry and pharmacology. J Clin Oncol 1988; 6: 1653-64.
3. Johnston PG, Fisher ER, Rockette HE et al. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 1994; 12: 2640-47.
4. Johnston PG, Lenz H-J, Leichman CG et al. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 1995; 55: 1407-12.
5. Peters GJ, van der Wilt CL, van Triest B et al. Thymidylate synthase and drug resistance. Eur J Cancer 1995; 31A: 1299-305.
6. Leichman CG, Lenz H-J, Leichman L et al. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 1997; 15: 3223-9.
7. Aschele C, Lonardi S, Monfardini S. Thymidylate synthase expression as a predictor of clinical response to fluoropyrimidine-based chemotherapy in advanced colorectal cancer. Cancer Treat Rev 2002; 28: 27-47.
8. L protein in colorectal cancer with preoperative peroral chemotherapy: TS as marker of unresponsiveness to 5-fluorouracil. Ann Cancer Res Ther 2003; 11: 73-94.
9. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993; 366: 704-7.
10. 1 control. Cancer Res 1995; 55: 4818-23.
11. Koh J, Enders GH, Dynlacht BD, Harlow E. Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature 1995; 375: 506-10.
12. Reddel RR. Genes involved in the control of cellular proliferative potential. Ann N Y Acad Sci 1998; 854: 8-19.
13. Sherr CJ. The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol 2001; 2: 731-7.
14. INK4A in archival human solid tumors: Correlation with retinoblastoma protein expression. Cancer Res 1995; 55: 6006-11.
15. Hu Y-X, Watanabe H, Ohtsubo K et al. Frequent loss of p16 expression and its correlation with clinicopathological parameters in pancreatic carcinoma. Clin Cancer Res 1997; 3: 1473-7.
16. Maeda K, Chung Y, Kang S et al. Cyclin D1 overexpression and prognosis in colorectal adenocarcinoma. Oncology 1998; 55: 145-51.
17. Naka T, Kobayashi M, Ashida K, Toyota N, Kaneko T, Kaibara N. Aberrant p16 (INK4) expression related to clinical stage and prognosis in patients with pancreatic cancer. Int J Oncol 1998; 12: 1111-16.
18. Palmqvist R, Stenling R, Öberg Å, Landberg G. Expression of cyclin D1 and retinoblastoma protein in colorectal cancer. Eur J Cancer 1998; 34: 1575-81.
19. 0 stage colorectal cancers: Association with DNA replication error and shorter survival. Oncology (Basel) 1999; 57: 149-56.
20. INK4a in anatomic and gender-specific subtypes of sporadic colorectal cancer. Cancer Epidemiol Biomarkers Prev 1999; 8: 501-6.
21. Omura K, Uno Y, Kawakami K et al. Expression of thymidylate synthase in human gastric and colorectal adenocarcinomas is upregulated by p16/INK4. Hepatogastroenterology 2000; 47: 742-5.
22. Sui L, Dong Y, Ohno M et al. Inverse expression of cdk4 and p16 in epithelial ovarian tumors. Gynecol Oncol 2000; 79: 230-37.
23. Esteller M, Gonzalez S, Risques RA et al. K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. J Clin Oncol 2001; 19: 299-304.
24. ink4a/CDKN2 identifies patients with good prognosis. J Clin Oncol 2001; 19: 2272-81.
25. Yi J, Wang ZW, Gang H et al. p16 gene methylation in colorectal cancers associated with Duke's staging. World J Gastroenterol 2001; 7: 722-5.
26. Marsh S, McKay JA, Curran S, Murray GI, Cassidy J, McLeod HL. Primary colorectal tumour is not an accurate predictor of thymidylate synthase in lymph node metastasis. Oncol Rep 2001; 9: 231-4.
27. McKay JA, Douglas JJ, Ross VG et al. Analysis of key cell-cycle checkpoint proteins in colorectal tumours. J Pathol 2002; 196: 386-93.
28. Namazie A, Alavi S, Olopade OI et al. Cyclin D1 amplification and p16 (MTS1/CDK4I) deletion correlate with poor prognosis in head and neck tumors. Laryngoscope 2002; 112: 472-81.
29. Zhao P, Hu Y-C, Talbot IC. Expressing patterns of p16 and CDK4 correlated to prognosis in colorectal carcinoma. World J Gastroenterol 2003; 9: 2202-6.
30. Sobin LH, Wittekind Ch, eds. UICC: TNM Classification of Malignant Tumours, 5th edn. New York: John Wiley, 1997.
31. Japanese Society for Cancer of the Colon and Rectum. Japanese Classification of Colorectal Carcinoma, 1st English edn. Tokyo: Kanehara Shuppan, 1997.
32. Fujii M. Using preoperative UFT to predict sensitivity to fluoropyrimidines in colorectal cancer. Oncology (Huntingt) 1999; 13: 55-60.
33. Kamoshida S, Matsuoka H, Matsuyama A, Shimomura Y, Maruta M, Tsutsumi Y. Reproducible and reliable immunohistochemical demonstration of thymidylate synthase in formalin-fixed, paraffin-embedded sections: Application of antigen retrieval in ethylenediaminetetraacetic acid solution. Acta Histochem Cytochem 2003; 36: 115-18.
34. Matsuura T, Fukuda Y, Fujitaka T, Nishisaka T, Sakatani T, Ito H. Preoperative treatment with tegafur suppositories enhances apoptosis and reduces the intratumoral microvessel density of human colorectal carcinoma. Cancer 2000; 88: 1007-15.
35. Ohhara M, Esumi M, Kurosu Y. Activation but not inactivation of the MTS1 gene is associated with primary colorectal carcinomas. Biochem Biophys Res Comm 1996; 226: 791-5.
36. Pollock PM, Pearson JV, Hayward NK. Compilation of somatic mutations of the CDKN2 gene in human cancers: Non-random distribution of base substitutions. Genes Chromosomes Cancer 1996; 15: 77-88.
37. Trzeciak L, Hennig E, Kolodziejski J, Nowacki M, Ostrowski J. Mutations, methylation and expression of CDKN2a/p16 gene in colorectal cancer and normal colonic mucosa. Cancer Lett 2001; 163: 17-23.
38. 1 arrest checkpoint in response to DNA damage. Mol Cell Biol 1998; 18: 378-87.
39. INK4 expression is associated with the increased sensitivity of human non-small cell lung cancer cells to DNA topoisomerase I inhibitors. Jpn J Cancer Res 1997; 88: 1009-16.
40. INK4a contributes to the outcome of cancer therapy. Cell 2002; 109: 335-46.
41. Mirjoret J-F, Barberi-Heyob M, Merlin J-L et al. Thymidylate synthase expression and activity: Relation to S-phase parameters and 5-fluorouracil sensitivity. Br J Cancer 1998; 78: 62-8.
42. Banerjee D, Gorlick R, Liefshitz A et al. Levels of E2F-1 expression are higher in lung metastasis of colon cancer as compared with hepatic metastasis and correlate with levels of thymidylate synthase. Cancer Res 2000; 60: 2365-7.
43. INK4a-mediated growth suppression. Mol Cell Biol 1996; 16: 1047-57.
44. Chetty R, Subramoney T, Singh J, Harilal P. Retinoblastoma (pRb) protein immunoexpression in colorectal cancer. Anticancer Res 1997; 17: 2593-7.
45. Harris CC. Structure and function of the p53 tumor suppressor gene: Clues for rational cancer therapeutic strategies. J Natl Cancer Inst 1996; 88: 1442-55.
46. Graziano F, Cascinu S. Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes' B colorectal cancer patients: How much evidence is enough? Ann Oncol 2003; 14: 1026-38.